Expertise in
8
conditions

Mark N. Gaze

London, ENG, GB 
Expertise in
8
conditions
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Mark Gaze practices in London, United Kingdom. Mr. Gaze is highly rated in 8 conditions, according to our data. His top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, Rhabdomyosarcoma, Thyroidectomy, and Orchiectomy.

His clinical research consists of co-authoring 111 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase I Study of 131-1 MIBG Followed by Nivolumab and Dinutuximab Beta in Children with Relapsed/refractory Neuroblastoma
A Phase I Study of 131-1 MIBG Followed by Nivolumab and Dinutuximab Beta in Children with Relapsed/refractory Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ch14.18/CHO
Study Phase: Phase 1
Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2024
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
A Cancer Research UK Phase I/II Study to Compare [124I]Meta-Iodobenzylguanidine (mIBG) Positron Emission Tomography/Computerised Tomography (PET/CT) to [123I]mIBG Imaging in Patients With Metastatic Neuroblastoma
A Cancer Research UK Phase I/II Study to Compare [124I]Meta-Iodobenzylguanidine (mIBG) Positron Emission Tomography/Computerised Tomography (PET/CT) to [123I]mIBG Imaging in Patients With Metastatic Neuroblastoma
Enrollment Status: Completed
Publish Date: June 21, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

111 Total Publications

Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study.
Correction to: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gaze's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile